1. Golidocitinib: First Approval.
- Author
-
Keam SJ
- Subjects
- Humans, Janus Kinase 1 antagonists & inhibitors, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors chemistry, Heterocyclic Compounds, 2-Ring pharmacology, Heterocyclic Compounds, 2-Ring therapeutic use, Heterocyclic Compounds, 2-Ring chemistry, China, Pyrazines pharmacology, Pyrazines therapeutic use, Bridged-Ring Compounds, Pyrimidines, Drug Approval, Lymphoma, T-Cell, Peripheral drug therapy
- Abstract
Golidocitinib (
® ) is an oral, potent, selective Janus kinase 1 (JAK1) inhibitor being developed by Dizal (Jiangsu) Pharmaceutical Co., Ltd for the treatment of cancer, including peripheral T cell lymphoma (PTCL). In June 2024, golidocitinib received conditional approval in China for the treatment of adult patients with relapsed or refractory (r/r) PTCL who have received at least one line of systemic treatment. This article summarizes the milestones in the development of golidocitinib leading to this first approval for the treatment of adults with PTCL., (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)- Published
- 2024
- Full Text
- View/download PDF